CURRICULUM VITAE
Name: Dr Lee Soo Chin;
Mailing address: Department of Haematology-Oncology, National University Health System (NUHS)
Level 7, 1E Kent Ridge Road, Singapore 119228
Tel: 65 67724621; Fax: 65 67775545; e-mail: csilsc@nus.edu.sg
Academic qualifications: MBBS, M.Med (Int Med), MRCP (UK), FAMS (Oncology), FRCP (Edinburgh)
Professional/ Academic Appointments:
Senior Consultant, Department of Haematology-Oncology, National University
Health System (NUHS), Singapore
Senior Clinician-Scientist Investigator, National Medical Research Council, Singapore
Senior Principal Investigator, Experimental Therapeutics Program, Cancer
Science Institute, Singapore
Office held in Other Professional Organisations:
Current Positions
Associate Director of Research, National University Cancer Institute, Singapore
Chairperson, Chapter of Medical Oncologists, Academy of Medicine, Singapore
Chairperson, National Healthcare Group (NHG), Domain-Specific Research
Ethics Review Board B
Director of Research, Department of Haematology-Oncology, NUHS
Member, Specialist Accreditation Board, Medical Oncology
Health Sciences Authority Pharmacogenetics Advisory Committee
01/08 to present
2006 to present
03/10 to present
04/09 to present
03/09 to 03/2011
04/08 to present
04/11 to present
04/08 to present
06/08 to present
Honours and Awards:
HMDP Fellowship (FY2000), Cancer Genetics, Johns Hopkins University, USA, 1999 to 2000
National Medical Research Council Junior Clinician Scientist Investigator Award, 2006
National Medical Research Council Senior Clinician Scientist Investigator Award, 2009
Current Grant support for Research
1. The National University Cancer Institute Centre Grant FY 2013-2016 (Co-Program Director) Start date:
April 2013; Source of grant: NMRC; Amount of grant: $26 million over 4 years
2. Development of predictive biomarkers and novel approaches to therapy in breast cancer: Principal
Investigator
Start date: October 2009; Source of grant: NMRC; Amount of grant: $1,750,000 over 5 years
LEE Soo Chin (MBBS, M.Med, MRCP, FAMS, FRCP)
Dr Lee obtained her medical degrees from the National University of Singapore and the
Royal College of Physicians, United Kingdom, and completed a fellowship in cancer
genetics at Johns Hopkins School of Medicine, United States. She is currently a Senior
Consultant in Medical Oncology at the National University Cancer Institute, Singapore and
Senior Principal Investigator at the Cancer Science Institute, Singapore. She is the
Associate Director of Research at the National University Cancer Institute, Singapore, and
Chairperson of the National Healthcare Group Domain-Specific Research Ethics Review
Board. She specializes in breast cancer and cancer genetics. Her research focus is on
breast cancer, pharmacogenetics, cancer genetics, and experimental therapeutics, and
she is the Principal Investigator of multiple multi-centre as well as investigator-initiated
breast cancer clinical trials. She was awarded the Singapore National Medical Research
Council Senior Clinician Scientist Award in 2009, and has more than 110 peer-reviewed
publications in major oncology and pharmacogenetics journals.
Selected Publications (out of 111)
1. The genomic landscape of nasopharyngeal carcinoma. Lin DC, Meng X, Hazawa M, Nagata Y, Varela
AM, Xu L, Sato Y, Liu LZ, Ding LW, Sharma A, Goh BC, Lee SC, Petersson BF, Yu FG, Macary P, Oo Mz,
Ha CS, Yang H, Ogawa S, Loh KS, Koeffler HP. Nature Genetics 2014, 46(8): 866-71
2. An ultra-high-throughput spiral microfluidic biochip for the enrichment of circulating tumor cells. ME
Warkiani, BL Khoo, DSW Tan, AAS Bhagat, WT Lim, YS Yap, SC Lee, RA Soo, JY Han, CT Lim. Analyst
2014; 139(13): 3245-55
3. Nanoprobe-based genetic testing. YB Zu, MH Tan, B Chowbay, SC Lee, HL Yap, MTM Lee, CP Chang,
LS Lu, JY Ying. Nano Today 2014; 9(2): 166-71
4. SPHK1 regulates proliferation and survival responses in triple-negative breast cancer. A Datta, SY Loo,
BH Huang, LK Wong, SSL Tan, TZ Tan, SC Lee, JP Thiery, YC Lim, WP Yong, YL Lam, AP Kumar, CT Yap.
Oncotarget 2014, March 27 (epub ahead of print)
5. Predicting survival of de novo metastatic breast cancer in Asian women: Systematic review and
validation study. H Miao, M Hartman, N Bhoo-Pathy, SC Lee, NA Taib, EY Tan, P Chan, KGM Moons, HS
Wong, J Goh, SM Rahim, CH Yip, HM Verkooijen. PLOS One 2014; 9(4): e93755
6. Body fat composition impacts the hematologic toxicities and pharmacokinetics of doxorubicin in Asian
breast cancer patients. AL Wong, KY Seng, EM Ong, LZ Wang, H Oscar, MT Cordero, R Copones, L Fan,
SH Tan, BC Goh, SC Lee. Breast Cancer Research and Treatment 2014; 144(1): 143-52
7. Inadequate family history assessment by oncologists is an important physician barrier to referral for
hereditary breast cancer evaluation. SGW Ow, YFL Yong, WS Chieng, PS Phyu, SC Lee. Clinical Oncology
(R Coll Radiol) 2014; 26(3): 174-5
8. Slanted spiral microfluidics for the ultra-fast, label-free isolation of circulating tumor cells. ME Warkiani,
GF Guan, BL Khoo, CL Wong, AS Bhagat, PK Chaudhuri, DSW Tan, WT Lim, SC Lee, PCY Chen, CT Lim,
JY Han. Lab on a Chip 2014, 14(1): 128-37
9. Hepatitis B virus reaction risk varies with different chemotherapy regimens commonly used in solid
tumors. WHY Ling, PP Soe, ASL Pang, SC Lee. British Journal of Cancer 2013; 108(10): 1931-5
10. Correlation of aldo-ketoreductase (AKR)1C3 genetic variant with doxorubicin pharmacodynamics in
Asian breast cancer patients. PJ Voon, HL Yap, CYT Ma, F Lu, ALA Wong, NS Sapari, R Soong, TIP Soh,
BC Goh, HS Lee, SC Lee. British Journal of Clinical Pharmacology 2013; 75(6): 1497-505
11. Brain metastases in Asian HER2-positive breast cancer patients: anti-HER2 treatment and their impact
on survival. YS Yap, GH Cornelio, BCR Devi, C Khorprasert, SB Kim, TY Kim, SC Lee, YH Park, JH Sohn, N
Sutandyo, DWY Wong, M Kobayashi, SH Landis, EM Yeoh, H Moon, J Ro. Brit J Cancer 2012; 107(7):
1075-82
12. Pharmacologic modulation strategies to reduce dose requirements of anti-cancer therapy while
preserving clinical efficacy. YK Zee, BC Goh, SC Lee. Future Oncology 2012, 8(6): 731-49
13. Gemcitabine and platinum pathway pharmacogenetics in Asian breast cancer patients. ALA Wong, HL
Yap, WL Yeo, R Soong, SS Ng, LZ Wang, MT Cordero, WP Yong, BC Goh, SC Lee. Cancer Genomics and
Proteomics 2011; 8(5): 255-9.
14. Impact of UDP-gluconoryltransferase 2B17 genotype on vorinsotat metabolism and clinical outcomes in
Asian breast cancer women. NS Wong, EZH Seah, LZ Wang, WL Yeo, HL Yap, B Chuah, YW Lim, PCS Ang,
BC Tai, R Lim, BC Goh, SC Lee. Pharmacogenetics and Genomics 2011; 21(11):760-8
15. LMTK3 expression in breast cancer; association with tumor phenotype and clinical outcome. J Stebbing,
A Filipovic, IO Ellis, AR Green H-J Lenz, RC Coombes, TT Wang, SC Lee, G Giamas. Breast Cancer Res
Treatment 2011; 132(2):537-44.
16. Effects of CYP4F2 and GGCX genetic variants on maintenance warfarin dose in a multi-ethnic Asian
population. SL Chan, BC Goh, KS Chia, B Chuah, A Wong, R Lim, SC Lee. Thrombosis and Haemostasis
2011; 105(6): 1100-2.
17. Phase I and pharmacodynamic study of an orally administered novel inhibitor of histone deacetylases,
SB939, in patients with refractory solid malignancies. WP Yong, BC Goh, RA Soo, HC Toh, K Ethirajulu, J
Wood, V Novotny-Diermayr, SC Lee, WL Yeo, D Chan, D Lim, E Seah, R Lim, J Zhu. Annals of Oncology
2011; 22(11):2516-22
18. Prognostic value of axillary lymph node status after neoadjuvant chemotherapy. Results from a
multicenter study. N Saxena, M Hartman, R Aziz, E Rapit, NB Pathy, SE Lim, P Iau, NA Tiab, I NeyroudCaspar, V Vinh-Hung, CH Yip, SC Lee, HM Verkooijen. Eur J Cancer 2011; 47(8): 1186-92.
19. Serial changes in the expression of breast cancer-related proteins in response to neoadjuvant
chemotherapy. BYS Chuah, T Putti, M Salto-Tellez, A Charlton, P Iau, SA Buhari, CI Wong, SH Tan, ALA
Wong, CW Chan, BC Goh, SC Lee. Annals of Oncology 2011; 22(8): 1748-54.
20. Exon sequencing and association analysis of EPHX1 genetic variants with maintenance warfarin dose in
a multi-ethnic Asian population. SL Chan, A Thalamuthu, BC Goh, KS Chia, B Chuah, A Wong, SC Lee.
Pharmacogenetics and Genomics 2011; 21(1): 35-41.
21. Pharmacokinetics and pharmacodynamis of docetaxel with or without ketoconazole modulation in
chemonaive breast cancer patients. YW Lim, BC Goh, LZ Wang, SH Tan, B Chuah, SE Lim, P Iau, SA
Buhari, CW Chan, N Sukri, MT Cordero, R Soo, SC Lee. Ann Oncol 2010; 21(11): 2175-82.
22. Phase II study of gemcitabine and carboplatin in metastatic breast cancers with prior exposure to
anthracyclines and taxanes. D Chan, WL Yeo, MT Cordero, CI Wong, B Chuah, R Soo, SH Tan, SE Lim, BC
Goh, SC Lee. Investigational New Drug 2010; 28(6): 859-65.
23. Post-treatment tumor gene expression signatures are more predictive of treatment outcomes than
baseline signatures in breast cancer. SC Lee, X Xu, WJ Chng, M Watson, YW Lim, CI Wong, P Iau, N Sukri,
SE Lim, HL Yap, SA Buhari, P Tan, JY Guo, B Chuah, HL McLeod, BC Goh. Pharmacogenetics and
genomics 2009; 19(11): 833-42.
24. Phase I and biomarker study of ABT-869, a multiple receptor tyrosine kinase inhibitor, in patients with
refractory solid malignancies. CI Wong, TS Koh, R Soo, S Hartono, CH Thng, E McKeegan, WP Yong, CS
Chen, SC Lee, J Wong, R Lim, N Sukri, SE Lim, AB Ong, J Steinberg, N Gupta, R Pradhan, R
Humerickhouse, BC Goh. J Clin Oncol 2009; 27(28): 4718-26.
25. Chemotherapy-induced tumor gene expression changes in human breast cancers. SC Lee, X Xu, YW
Lim, P Iau, N Sukri, SE Lim, HL Yap, WL Yeo, P Tan, SH Tan, H McLeod, BC Goh. Pharmacogenetics and
Genomics 2009; 19(3): 181-92.
26. Pharmacogenetics in Breast Cancer Therapy. SH Tan, SC Lee, BC Goh, J Wong. Clin Cancer Research
2008; 14(24): 8027-41.
27. Recurring MLH1 deleterious mutations in unrelated Chinese Lynch syndrome families in Singapore. HL
Yap, WS Chieng, RC Lim, R Lim, R Soo, JY Guo, SC Lee. Familial Cancer 2009; 8(2): 85-94.
28. A pharmacodynamic model for the time course of tumor shrinkage by gemcitabine + carboplatin in nonsmall cell lung cancer patients. LS Tham, LZ Wang, R Soo, SC Lee, HS Lee, WP Yong, BC Goh, N Holford.
Clinical Cancer Research 2008; 14(13): 4213-8.
29. Genotype of human carbonyl reductase CBR3 correlates with doxorubicin disposition and toxicity. L Fan,
BC Goh, CI Wong, N Sukri, SE Lim, SH Tan, JY Guo, R Lim, HL Yap, YM Khoo, P Iau, HS Lee, SC Lee.
Pharmacogenetics and genomics 2008; 18(7): 623-31.